Overview

Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli

Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Mahidol University
Treatments:
Colistin